Balance Sheet
Cash Flow Statement
Capital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

PAVmed (PAVM) Change in Cash (2016 - 2025)

PAVmed has reported Change in Cash over the past 5 years, most recently at -$1.6 million for Q4 2025.

  • For Q4 2025, Change in Cash fell 472.62% year-over-year to -$1.6 million; the TTM value through Dec 2025 reached $353000.0, up 172.19%, while the annual FY2025 figure was $353000.0, 101.91% up from the prior year.
  • Change in Cash for Q4 2025 was -$1.6 million at PAVmed, down from -$901000.0 in the prior quarter.
  • Over five years, Change in Cash peaked at $39.9 million in Q4 2021 and troughed at -$17.0 million in Q4 2022.
  • A 5-year average of $474526.3 and a median of -$901000.0 in 2025 define the central range for Change in Cash.
  • Biggest five-year swings in Change in Cash: crashed 3012.74% in 2023 and later surged 3624.32% in 2025.
  • Year by year, Change in Cash stood at $39.9 million in 2021, then tumbled by 142.69% to -$17.0 million in 2022, then soared by 60.28% to -$6.8 million in 2023, then surged by 106.2% to $420000.0 in 2024, then crashed by 472.62% to -$1.6 million in 2025.
  • Business Quant data shows Change in Cash for PAVM at -$1.6 million in Q4 2025, -$901000.0 in Q3 2025, and $1.3 million in Q2 2025.